Unilateral Episcleritis Following COVID-19 Booster Vaccination of a Crohn’s Disease Patient: A Case Report and Review of the Literature

References

• World Health Organization. Who coronavirus (COVID-19) dashboard. World Health Organization. Available from: https://covid19.who.int/. Accessed December 12, 2022.
   Google Scholar
• Solís Arce JS, Warren SS, Meriggi NF, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385–1394. doi:10.1038/s41591-021-01454-y
   PubMed Web of Science ®Google Scholar
• Sen M, Honavar SG. After the storm: ophthalmic manifestations of COVID-19 vaccines. Indian J Ophthalmol. 2021;69(12):3398–3420. doi:10.4103/ijo.IJO_2824_21
   PubMed Web of Science ®Google Scholar
• Bolletta E, Iannetta D, Mastrofilippo V, et al. Uveitis and other ocular complications following COVID-19 vaccination. J Clin Med. 2021;10(24):5960. doi:10.3390/jcm10245960
   PubMed Web of Science ®Google Scholar
• Ng XL, Betzler BK, Testi I, et al. Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm. 2021;29(6):1216–1224. doi:10.1080/09273948.2021.1976221
   PubMed Web of Science ®Google Scholar
• Wang MTM, Niederer RL, McGhee CNJ, Danesh-Meyer HV. COVID-19 vaccination and the eye. Am J Ophthalmol. 2022;240:79–98. doi:10.1016/j.ajo.2022.02.011
   PubMed Web of Science ®Google Scholar
• Honik G, Wong IG, Gritz DC. Incidence and prevalence of episcleritis and scleritis in Northern California. Cornea. 2013;32(12):1562–1566. doi:10.1097/ICO.0b013e3182a407c3
   PubMed Web of Science ®Google Scholar
• Schonberg S, Stokkermans TJ. Episcleritis. StatPearls; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534796/. Accessed December 13, 2022.
   Google Scholar
• Pichi F, Aljneibi S, Neri P, et al. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol. 2021;139(10):1131. doi:10.1001/jamaophthalmol.2021.3477
   PubMed Web of Science ®Google Scholar
• Pang K, Pan L, Guo H, Wu X. Case report: associated ocular adverse reactions with inactivated COVID-19 vaccine in China case report. Front Med. 2022;2022:8.
   Google Scholar
• Testi I, Brandão-de-resende C, Agrawal R, Pavesio C. Ocular inflammatory events following COVID-19 vaccination: a multinational case series. J Ophthalmic Inflamm Infect. 2022;12(1). doi:10.1186/s12348-021-00275-x
   Web of Science ®Google Scholar
• Agarwal M, Dutta Majumder P, Babu K, et al. Drug-induced uveitis: a review. Indian J Ophthalmol. 2020;68(9):1799–1807. doi:10.4103/ijo.IJO_816_20
   Google Scholar
• Cunningham ET, Moorthy RS, Fraunfelder FW, Zierhut M. Vaccine-Associated Uveitis. Ocul Immunol Inflamm. 2019;27(4):517–520. doi:10.1080/09273948.2019.1626188
   Google Scholar
• Ng XL, Betzler BK, Ng S, et al. The eye of the storm: COVID-19 vaccination and the eye. Ophthalmol Ther. 2021;11(1):81–100. doi:10.1007/s40123-021-00415-5
   Google Scholar
• Lim WW, Mak L, Leung GM, et al. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe. 2021;2185 (9):e423. doi:10.1016/S2666-5247(21)00177-4
   Google Scholar
• Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis. 2007;22(9):1027–1030. doi:10.1007/s00384-007-0275-1
   Google Scholar
• Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–1992. doi:10.1097/MIB.0000000000000392
   Google Scholar
• Troncosco LL, Biancardi AL, de Moraes HV, Zalrman C. Ophthalmic manifestations in patients with inflammatory bowel disease: a review. World 175 J Gastroenterol. 2017;23(32):5836–5848. doi:10.3748/wjg.v23.i32.5836
   Google Scholar
• Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5. doi:10.1186/s13223-020-0403-9
   Google Scholar
• Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(9):540–546.
   Google Scholar
• Banaszkiewicz A, Targońska B, Kowalska-Duplaga K, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(7):1607–1614. doi:10.1097/MIB.0000000000000406
   PubMed Web of Science ®Google Scholar
• deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–647. doi:10.1097/MIB.0000000000000615
   PubMed Web of Science ®Google Scholar
• Wasan SK, Zullow S, Berg A, et al. Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression. Inflamm Bowel Dis. 2016;22(6):1391–1396. doi:10.1097/MIB.0000000000000743
   PubMed Web of Science ®Google Scholar
• Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022;7(4):342–352. doi:10.1016/S2468-1253(22)00005-X
   PubMed Web of Science ®Google Scholar
• Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116(8):1746–1751. doi:10.14309/ajg.0000000000001342
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Moorthy MS, Cunningham ET. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29(6):588–603. doi:10.1097/ICU.0000000000000530
   PubMed Web of Science ®Google Scholar
• Benage M, Fraunfelder FW. Vaccine-Associated Uveitis. Mo Med. 2016;113(1):48–52.
   PubMedGoogle Scholar
• Akpek EK, Uy HS, Christen W, et al. Severity of episcleritis and systemic disease association. Ophthalmology. 1999;106(4):729–731. doi:10.1016/S0161-6420(99)90157-4
   PubMed Web of Science ®Google Scholar
• de la Maza M S, Molina N, Gonzalez-Gonzalez LA, et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43–50. doi:10.1016/j.ophtha.2011.07.013
   PubMed Web of Science ®Google Scholar
• Daniel Diaz J, Sobol EK, Gritz DC. Treatment and management of scleral disorders. Surv Ophthalmol. 2016;61(6):702–717. doi:10.1016/j.survophthal.2016.06.002
   PubMed Web of Science ®Google Scholar
• Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163–191. doi:10.1136/bjo.60.3.163
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101(2):389–396. doi:10.1016/S0161-6420(94)31325-X
   PubMed Web of Science ®Google Scholar